Damora Therapeutics (DMRA) Joins Russell Indexes With Valuation Still Looking About Right

Simply Wall St.

07/07

Damora Therapeutics (DMRA) has been added to a wide range of Russell indices, including the Russell 2000, 2500 and 3000 families. This change can influence institutional demand and trading activity. ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2649609858"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649609858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649609858?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-07 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649609858","market":"hk","top_or_hot":-1,"title":"Damora Therapeutics (DMRA) Joins Russell Indexes With Valuation Still Looking About Right","media":"Simply Wall St.","content":"<div>\n<p>Damora Therapeutics (DMRA) has been added to a wide range of Russell indices, including the Russell 2000, 2500 and 3000 families. This change can influence institutional demand and trading activity. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-joins-russell-indexes-with-valuatio\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Damora Therapeutics (DMRA) Joins Russell Indexes With Valuation Still Looking About Right</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDamora Therapeutics (DMRA) Joins Russell Indexes With Valuation Still Looking About Right\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-07 11:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-joins-russell-indexes-with-valuatio><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Damora Therapeutics (DMRA) has been added to a wide range of Russell indices, including the Russell 2000, 2500 and 3000 families. This change can influence institutional demand and trading activity. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-joins-russell-indexes-with-valuatio\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-joins-russell-indexes-with-valuatio","article_id":"2649609858","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-joins-russell-indexes-with-valuatio","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649609858","pubTimestamp":1783395154,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Damora Therapeutics (DMRA) has been added to a wide range of Russell indices, including the Russell 2000, 2500 and 3000 families. This change can influence institutional demand and trading activity.\nSee our latest analysis for Damora Therapeutics.\nDamora Therapeutics' recent additions to multiple Russell indices come alongside strong recent share price momentum, with a 7 day share price return of 23.09% and a 30 day share price return of 41.84%. However, the 5 year total shareholder return is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","DMRA":"DAMORA THERAPEUT","BK4139":"生物科技"},"translate_title":"Damora Therapeutics(DMRA)加入罗素指数，估值仍然合适","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DMRA":1.5,"LENZ":1.5},"content_text":"Damora Therapeutics (DMRA) has been added to a wide range of Russell indices, including the Russell 2000, 2500 and 3000 families. This change can influence institutional demand and trading activity. See our latest analysis for Damora Therapeutics. Damora Therapeutics' recent additions to multiple Russell indices come alongside strong recent share price momentum, with a 7 day share price return of 23.09% and a 30 day share price return of 41.84%. However, the 5 year total shareholder return is down 73.63%, highlighting how volatile the journey has been. If this kind of sharp move has your attention, it can be helpful to compare Damora Therapeutics with other biopharma peers using a focused set of healthcare AI opportunities via the 40 healthcare AI stocks. Damora Therapeutics now sits in a cluster of Russell indices after a sharp recent run, which can make the story look stronger at a glance. The real test is whether the current price fairly reflects that story. AdvertisementPreferred Price-to-Book Multiple of 4.8x: Is It Justified? With Damora Therapeutics closing at $29.80 and trading on a P/B ratio of 4.8x, the stock is priced well above the broader US biopharma sector on this metric, yet sits below the average of its closer peer group. The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For early stage biopharma businesses like Damora Therapeutics that are currently loss making and generating less than $1 million in revenue, P/B is often used because earnings and revenue based multiples are not meaningful. According to the statements data, Damora Therapeutics screens as expensive versus the wider US Biotechs industry, where the average P/B ratio is 2.8x. At the same time, it looks cheap versus a selected peer set that trades around 39.6x P/B, so the market is assigning Damora Therapeutics a valuation that sits between the industry as a whole and some higher priced comparables. If you want to see where this valuation could shift if the market reassesses what a \"fair\" P/B looks like for Damora Therapeutics, the detailed regression based work sits behind the See what the numbers say about this price — find out in our valuation breakdown.. Result: Price-to-book of 4.8x (ABOUT RIGHT) However, Damora Therapeutics still carries clear risks, including ongoing net losses of $235.089 million and revenue at effectively zero. This could strain sentiment if funding tightens. Find out about the key risks to this Damora Therapeutics narrative. Next Steps With Damora Therapeutics presenting both clear risks and some potential rewards, it may be helpful to act promptly and evaluate the situation using your own judgement with the 1 key reward and 4 important warning signs. Looking for more investment ideas beyond Damora Therapeutics? If Damora Therapeutics has caught your interest, broaden your watchlist with other focused ideas so you are not relying on a single story.  Spot potential turnaround stories early by scanning through 20 elite penny stocks with strong financials that pair small size with more robust financial profiles. Target quality at a measured price by reviewing the 41 high quality undervalued stocks that combine resilient cash flows with stronger balance sheets. Strengthen your income toolkit by checking out the 8 dividend fortresses built around higher yielding companies that still aim for staying power.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}